Avidity Biosciences Acquired by Novartis for $72 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Should l Buy RNA?
Source: PRnewswire
- Acquisition Investigation: Halper Sadeh LLC is investigating Avidity Biosciences, Inc. (NASDAQ:RNA) for its sale to Novartis at $72 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders.
- Shareholder Rights: The law firm encourages Avidity shareholders to contact them immediately to learn about their rights and options, indicating that shareholder interests may be at risk in the transaction.
- Merger Scrutiny: Halper Sadeh LLC is also examining the merger between Third Coast Bancshares, Inc. (NYSE:TCBX) and Keystone Bancshares, Inc., which may involve fiduciary duty issues affecting shareholders.
- Legal Support: The firm offers legal assistance on a contingency fee basis, ensuring that affected investors can seek increased compensation and disclosures without upfront costs, highlighting their commitment to protecting shareholder rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNA
Wall Street analysts forecast RNA stock price to rise
9 Analyst Rating
2 Buy
7 Hold
0 Sell
Hold
Current: 72.830
Low
72.00
Averages
75.63
High
96.00
Current: 72.830
Low
72.00
Averages
75.63
High
96.00
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Significant Efficacy: Del-desiran effectively delivered siRNA to muscle, resulting in an approximately 40% mean reduction in DMPK mRNA across all treated participants, indicating the potential clinical value of this therapy for myotonic dystrophy type 1 (DM1).
- Functional Improvements: Participants exhibited significant improvements in multiple functional assessments post-treatment, including hand function, muscle strength, and activities of daily living, highlighting del-desiran's potential to enhance patient quality of life.
- Good Safety Profile: Most treatment-emergent adverse events were mild or moderate and did not lead to participant discontinuation, indicating that del-desiran has an acceptable safety and tolerability profile, which bolsters its credibility as a potential treatment option.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR study, which is expected to be the first approved drug for DM1, further validating the efficacy and safety of del-desiran.
See More
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Clinical Trial Results: Avidity Biosciences' del-desiran demonstrated efficacy in the Phase 1/2 MARINA trial for patients with myotonic dystrophy type 1, achieving approximately 40% mean reduction in DMPK mRNA, providing new hope for treatment.
- Multiple Improvement Metrics: The treatment showed significant improvements across various measures including muscle function, strength, mobility, and patient-reported outcomes, indicating that del-desiran could become a transformational therapy for patients, addressing the urgent need for effective treatments.
- Safety and Tolerability: The trial results indicated that del-desiran has an acceptable safety and tolerability profile, with most adverse events being mild or moderate, laying a solid foundation for its future clinical applications and boosting confidence among investors and patients.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR trial, with topline data expected in the second half of 2026, and if results are positive, it could become the first approved drug for DM1, representing significant market potential.
See More
Avidity Biosciences Announces Share Distribution for Spin-Off
- Share Distribution Announcement: Avidity Biosciences has announced a share distribution on February 12, 2026, where holders of Avidity common stock will receive one share of Atrium Therapeutics for every ten shares held, aimed at enhancing company value through the spin-off.
- Merger Progress: This share distribution is linked to Avidity's acquisition by Novartis, with completion contingent on specific conditions including shareholder approval, indicating the company's strategic positioning in merger integration.
- Innovative Drug Platform: Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform is advancing clinical projects targeting rare muscle diseases, showcasing its innovative capabilities in RNA therapeutics, which could yield long-term growth potential for the company.
- Market Outlook: Through collaboration with Novartis, Avidity plans to expand its pipeline in cardiology and immunology, further enhancing its market competitiveness and addressing the growing healthcare demands.
See More
Avidity Biosciences Announces Spin-Off Plan
- Shareholder Distribution Plan: Avidity Biosciences has announced a record date of February 12, 2026, for the pro rata distribution of Atrium Therapeutics shares, providing one share for every ten Avidity shares held, aimed at enhancing shareholder value and preparing for the upcoming merger.
- Merger and Spin-Off Progress: The completion of the merger and spin-off is subject to specific closing conditions, including Avidity shareholder approval, indicating the company's strategic focus on resource integration and business optimization, which may impact future market performance.
- Innovative Drug Platform: Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform is advancing clinical projects targeting rare muscle diseases, showcasing the company's technological leadership in biopharmaceuticals, which is expected to drive future revenue growth.
- Market Outlook: Through the merger with Novartis, Avidity aims to expand its influence in the precision cardiology sector, potentially attracting more investor interest in its long-term growth prospects and enhancing its competitive position in the market.
See More
Halper Sadeh LLC Investigates Multiple Companies for Securities Violations
- Two Harbors Transaction: Halper Sadeh LLC is investigating Two Harbors Investment Corp. (NYSE: TWO) for its sale to UWM Holdings Corporation, which involves an exchange of 2.3328 shares of UWM Class A Common Stock for each share of Two Harbors common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Avidity Biosciences Acquisition: Avidity Biosciences, Inc. (NASDAQ: RNA) is being sold to Novartis for $72.00 per share in cash, and Halper Sadeh LLC is assessing the implications of this transaction on shareholder rights and options.
- CVB Financial Merger: CVB Financial Corp. (NASDAQ: CVBF) is merging with Heritage Commerce Corp., which will result in CVB shareholders owning approximately 77% of the combined entity, prompting Halper Sadeh LLC to investigate the compliance of this merger.
- Tamboran Resources Merger: Tamboran Resources Corporation (NYSE: TBN) is merging with Falcon Oil & Gas Ltd., allowing Tamboran shareholders to own 73.2% of the combined company, and Halper Sadeh LLC may seek increased compensation and disclosures for shareholders regarding this deal.
See More
Earnings Momentum Review: BAX and Others Rated D
- Earnings Momentum Ratings: As the earnings season kicks off, Baxter International (BAX) and others are rated D for earnings momentum, indicating significant pressure on profitability that may undermine investor confidence.
- Multiple Companies Rated: Companies like Biogen (BIIB), Natera (NTRA), and Revolution Medicines (RVMD) also received D ratings, suggesting a notable decline in earnings expectations that could lead to stock price volatility.
- Market Impact: These ratings reflect a broader weakening of earnings momentum in the healthcare sector, potentially affecting the performance of related healthcare ETFs (such as XLV, VHT), prompting investors to reassess risks.
- Industry Outlook: As the earnings season progresses, market attention on healthcare stocks, particularly those with weak earnings momentum, may trigger broader industry adjustments and shifts in investment strategies.
See More
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Significant Efficacy: Del-desiran effectively delivered siRNA to muscle, resulting in an approximately 40% mean reduction in DMPK mRNA across all treated participants, indicating the potential clinical value of this therapy for myotonic dystrophy type 1 (DM1).
- Functional Improvements: Participants exhibited significant improvements in multiple functional assessments post-treatment, including hand function, muscle strength, and activities of daily living, highlighting del-desiran's potential to enhance patient quality of life.
- Good Safety Profile: Most treatment-emergent adverse events were mild or moderate and did not lead to participant discontinuation, indicating that del-desiran has an acceptable safety and tolerability profile, which bolsters its credibility as a potential treatment option.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR study, which is expected to be the first approved drug for DM1, further validating the efficacy and safety of del-desiran.
See More
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Clinical Trial Results: Avidity Biosciences' del-desiran demonstrated efficacy in the Phase 1/2 MARINA trial for patients with myotonic dystrophy type 1, achieving approximately 40% mean reduction in DMPK mRNA, providing new hope for treatment.
- Multiple Improvement Metrics: The treatment showed significant improvements across various measures including muscle function, strength, mobility, and patient-reported outcomes, indicating that del-desiran could become a transformational therapy for patients, addressing the urgent need for effective treatments.
- Safety and Tolerability: The trial results indicated that del-desiran has an acceptable safety and tolerability profile, with most adverse events being mild or moderate, laying a solid foundation for its future clinical applications and boosting confidence among investors and patients.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR trial, with topline data expected in the second half of 2026, and if results are positive, it could become the first approved drug for DM1, representing significant market potential.
See More
Avidity Biosciences Announces Share Distribution for Spin-Off
- Share Distribution Announcement: Avidity Biosciences has announced a share distribution on February 12, 2026, where holders of Avidity common stock will receive one share of Atrium Therapeutics for every ten shares held, aimed at enhancing company value through the spin-off.
- Merger Progress: This share distribution is linked to Avidity's acquisition by Novartis, with completion contingent on specific conditions including shareholder approval, indicating the company's strategic positioning in merger integration.
- Innovative Drug Platform: Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform is advancing clinical projects targeting rare muscle diseases, showcasing its innovative capabilities in RNA therapeutics, which could yield long-term growth potential for the company.
- Market Outlook: Through collaboration with Novartis, Avidity plans to expand its pipeline in cardiology and immunology, further enhancing its market competitiveness and addressing the growing healthcare demands.
See More
Avidity Biosciences Announces Spin-Off Plan
- Shareholder Distribution Plan: Avidity Biosciences has announced a record date of February 12, 2026, for the pro rata distribution of Atrium Therapeutics shares, providing one share for every ten Avidity shares held, aimed at enhancing shareholder value and preparing for the upcoming merger.
- Merger and Spin-Off Progress: The completion of the merger and spin-off is subject to specific closing conditions, including Avidity shareholder approval, indicating the company's strategic focus on resource integration and business optimization, which may impact future market performance.
- Innovative Drug Platform: Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform is advancing clinical projects targeting rare muscle diseases, showcasing the company's technological leadership in biopharmaceuticals, which is expected to drive future revenue growth.
- Market Outlook: Through the merger with Novartis, Avidity aims to expand its influence in the precision cardiology sector, potentially attracting more investor interest in its long-term growth prospects and enhancing its competitive position in the market.
See More
Halper Sadeh LLC Investigates Multiple Companies for Securities Violations
- Two Harbors Transaction: Halper Sadeh LLC is investigating Two Harbors Investment Corp. (NYSE: TWO) for its sale to UWM Holdings Corporation, which involves an exchange of 2.3328 shares of UWM Class A Common Stock for each share of Two Harbors common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Avidity Biosciences Acquisition: Avidity Biosciences, Inc. (NASDAQ: RNA) is being sold to Novartis for $72.00 per share in cash, and Halper Sadeh LLC is assessing the implications of this transaction on shareholder rights and options.
- CVB Financial Merger: CVB Financial Corp. (NASDAQ: CVBF) is merging with Heritage Commerce Corp., which will result in CVB shareholders owning approximately 77% of the combined entity, prompting Halper Sadeh LLC to investigate the compliance of this merger.
- Tamboran Resources Merger: Tamboran Resources Corporation (NYSE: TBN) is merging with Falcon Oil & Gas Ltd., allowing Tamboran shareholders to own 73.2% of the combined company, and Halper Sadeh LLC may seek increased compensation and disclosures for shareholders regarding this deal.
See More
Earnings Momentum Review: BAX and Others Rated D
- Earnings Momentum Ratings: As the earnings season kicks off, Baxter International (BAX) and others are rated D for earnings momentum, indicating significant pressure on profitability that may undermine investor confidence.
- Multiple Companies Rated: Companies like Biogen (BIIB), Natera (NTRA), and Revolution Medicines (RVMD) also received D ratings, suggesting a notable decline in earnings expectations that could lead to stock price volatility.
- Market Impact: These ratings reflect a broader weakening of earnings momentum in the healthcare sector, potentially affecting the performance of related healthcare ETFs (such as XLV, VHT), prompting investors to reassess risks.
- Industry Outlook: As the earnings season progresses, market attention on healthcare stocks, particularly those with weak earnings momentum, may trigger broader industry adjustments and shifts in investment strategies.
See More
